Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family.

Tomasina J, Malzert-Freon A, Giffard F, Brotin E, Louis MH, Abeilard E, Rault S, Gauduchon P, Poulain L.

J Ovarian Res. 2013 Jun 5;6(1):38. doi: 10.1186/1757-2215-6-38.

2.

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.

Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, Denoyelle C, Gauduchon P, Poulain L.

Mol Cancer Ther. 2009 Nov;8(11):3162-70. doi: 10.1158/1535-7163.MCT-09-0493. Epub 2009 Nov 3.

3.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
4.

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.

Bonnefond ML, Lambert B, Giffard F, Abeilard E, Brotin E, Louis MH, Gueye MS, Gauduchon P, Poulain L, N'Diaye M.

Apoptosis. 2015 Apr;20(4):535-50. doi: 10.1007/s10495-015-1095-3.

5.

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells.

Lincet H, Kafara P, Giffard F, Abeilard-Lemoisson E, Duval M, Louis MH, Poulain L, Icard P.

J Ovarian Res. 2013 Oct 8;6(1):72. doi: 10.1186/1757-2215-6-72.

6.

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.

Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 Apr;105(1):31-44. Epub 2007 Feb 1.

PMID:
17275076
7.

Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.

Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L.

Int J Cancer. 2010 Feb 15;126(4):885-95. doi: 10.1002/ijc.24787.

8.

First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.

Gloaguen C, Voisin-Chiret AS, Sopkova-de Oliveira Santos J, Fogha J, Gautier F, De Giorgi M, Burzicki G, Perato S, Pétigny-Lechartier C, Simonin-Le Jeune K, Brotin E, Goux D, N'Diaye M, Lambert B, Louis MH, Ligat L, Lopez F, Juin P, Bureau R, Rault S, Poulain L.

J Med Chem. 2015 Feb 26;58(4):1644-68. doi: 10.1021/jm500672y. Epub 2015 Feb 4.

PMID:
25585174
9.

Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.

Eichhorn JM, Alford SE, Sakurikar N, Chambers TC.

Exp Cell Res. 2014 Apr 1;322(2):415-24. doi: 10.1016/j.yexcr.2014.02.010. Epub 2014 Feb 17.

10.

Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.

Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 May;105(2):373-84. Epub 2007 Feb 5.

PMID:
17276501
11.

Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.

Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L.

Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8.

12.

Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.

Mattoo AR, Zhang J, Espinoza LA, Jessup JM.

Clin Cancer Res. 2014 Nov 1;20(21):5446-55. doi: 10.1158/1078-0432.CCR-14-1134. Epub 2014 Sep 10.

13.

The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.

Cao X, Yap JL, Newell-Rogers MK, Peddaboina C, Jiang W, Papaconstantinou HT, Jupitor D, Rai A, Jung KY, Tubin RP, Yu W, Vanommeslaeghe K, Wilder PT, MacKerell AD Jr, Fletcher S, Smythe RW.

Mol Cancer. 2013 May 16;12(1):42. doi: 10.1186/1476-4598-12-42.

14.

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.

Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.

Breast Cancer Res. 2012 Jun 15;14(3):R96.

15.

Nutrient Starvation Sensitizes Human Ovarian Cancer SKOV3 Cells to BH3 Mimetic via Modulation of Mitochondrial Dynamics.

Wang S, Mao Y, Xi S, Wang X, Sun L.

Anat Rec (Hoboken). 2017 Feb;300(2):326-339. doi: 10.1002/ar.23454. Epub 2016 Sep 28.

PMID:
27486855
16.

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.

Mol Med. 2011;17(11-12):1262-74. doi: 10.2119/molmed.2011.00176. Epub 2011 Aug 19.

17.

Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.

Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V.

Gynecol Oncol. 1998 Sep;70(3):398-403.

PMID:
9790794
18.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

19.

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.

Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.

20.

Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

Okumura K, Huang S, Sinicrope FA.

Clin Cancer Res. 2008 Dec 15;14(24):8132-42. doi: 10.1158/1078-0432.CCR-08-1665.

Supplemental Content

Support Center